Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

Laatste koers (eur) Verschil Volume
25,540   -0,160   (-0,62%) Dagrange 25,040 - 25,640 79.320   Gem. (3M) 88,4K

Galapagos februari 2018

4.984 Posts
Pagina: «« 1 ... 194 195 196 197 198 ... 250 »» | Laatste | Omlaag ↓
  1. forum rang 4 greenback 23 februari 2018 13:39
    quote:

    djyves schreef op 23 februari 2018 13:34:

    voor mij is en blijf het een teleurstellend aandeel, k denk dat we de 100 € zelfs de 2 volgende maanden nog niet gaan zien.
    Niemand dwingt je het aandeel te hebben of te houden he. Dat is nou het mooie van aandelen, je kunt ze kopen en verkopen en doorgaan naar de volgende.
  2. Al Kipone 23 februari 2018 13:41
    quote:

    djyves schreef op 23 februari 2018 13:34:

    voor mij is en blijf het een teleurstellend aandeel, k denk dat we de 100 € zelfs de 2 volgende maanden nog niet gaan zien.
    Dat gevoel had ik altijd met FC Twente. Leuk, maar nooit echt top. In arren moede ben ik uiteindelijk fan van Heracles geworden.
  3. Al Kipone 23 februari 2018 13:46
    FYI:

    During the RBC Capital HC Conference on 2/21, $GILD's Robin Washington indicated $28 bil of repatriated cash came back to US. Norbert indicated $SGMO had choice of buyout or collaboration. This says there was an offer made and it was NOT high enough. $3.01 BIL = $35.40/sh.

    (SGMO took the partnership....)
  4. [verwijderd] 23 februari 2018 13:48
    quote:

    Sir Chanticleer schreef op 23 februari 2018 13:46:

    FYI:

    During the RBC Capital HC Conference on 2/21, $GILD's Robin Washington indicated $28 bil of repatriated cash came back to US. Norbert indicated $SGMO had choice of buyout or collaboration. This says there was an offer made and it was NOT high enough. $3.01 BIL = $35.40/sh.

    (SGMO took the partnership....)
    Kan je dat eens in volzinnen uitleggen?
  5. Al Kipone 23 februari 2018 13:51
    quote:

    spitfighter schreef op 23 februari 2018 13:48:

    [...]
    Kan je dat eens in volzinnen uitleggen?
    Translate a piece of text, satisfy a man for an hour. Tell him to learn English and set him on path to eternal bliss.

    (nee dus)

    EDIT: bovenstaande klinkt wellicht wat harder dan de bedoeling was, maar ik denk dat ik de zinnen niet voller kan maken.
  6. [verwijderd] 23 februari 2018 13:58
    Geen probleem. Hieronder een (voor mij) duidelijker stukje tekst. Toch bedankt for raising awareness.

    Gilead's Kite (GILD) and Sangamo Therapeutics (SGMO) Announce Pact to Develop Next-Generation Engineered Cell Therapies For Treatment of Cancer

    Kite, a Gilead Company (Nasdaq: GILD) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the companies have entered into a worldwide collaboration using Sangamo's zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology.

    Kite will use Sangamo's ZFN technology to modify genes to develop next-generation cell therapies for autologous and allogeneic use in treating different cancers. Allogeneic cell therapies from healthy donor cells or from renewable stem cells would provide a potential treatment option that can be accessed directly within the oncology infusion center, thus reducing the time to infusion for patients.

    Under the terms of the agreement, Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, aggregated across 10 or more products utilizing Sangamo's technology, based on the achievement of certain research, development, regulatory and successful commercialization milestones. Sangamo would also receive tiered royalties on sales of potential future products resulting from the collaboration. Kite will be responsible for all development, manufacturing and commercialization of products under the collaboration, and will be responsible for agreed upon expenses incurred by Sangamo.

    "This collaboration between Kite and Sangamo brings together two leading platforms to develop best-in-class cell therapies in oncology," said Sandy Macrae, President and Chief Executive Officer of Sangamo. "We are excited by Kite's commitment to driving innovation in this field and look forward to working together to realize the full promise of cell therapy in treating cancer."
4.984 Posts
Pagina: «« 1 ... 194 195 196 197 198 ... 250 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.